Tata Consultancy Services has been positioned as a Leader in the Everest Group PEAK Matrix for Life Sciences Operations Services.
In an assessment of 31 life sciences BPS providers, TCS was placed highest for Vision and Capability. According to the report, TCS is one of the largest providers of services in life sciences operations and offers end-to-end services across the complete value chain including pharmacovigilance, clinical data management, biostatistics, supply chain management, regulatory affairs, and medical writing.
Cited as a strength was TCS’ ADD platform (driven by cognitive automation), for which strong use cases have been noted in the market. The company’s significant investments in developing next-generation solutions and platforms for core R&D functions, including genomics secondary analysis and lab informatics, were highlighted as a key strength.
The report goes on to say that clients have been very vocal about TCS’ strong domain expertise, high quality of work, and leverage of automation tools and solutions (including ADD platform).
“TCS leverages its deep domain expertise and cutting-edge technologies to help life sciences customers reimagine, speed-up and scale mission critical pursuits across the value chain,” said Vikas Jain, Global Co-Head, Life Sciences, TCS. “This leadership position is a reflection of our vision, investments in innovative solutions, breadth of our services portfolio, and the trust shown by our clients.”
TCS collaborates with leading life sciences companies to enable their digital transformation journey with a full set of advisory and services and solutions including data and analytics, predictive and prescriptive analytics, advanced cloud-based platform solutions, genomics research, cognitive search, and digital labs.
Early investments in research and innovation around key trends and intellectual property, have helped TCS gain significant scale and depth across the life sciences value chain.
TCS offers a full set of business operations and transformation services and solutions including advisory services, predictive and prescriptive analytics, clinical operations, regulatory services, laboratory platforms, AI / ML solutions, pharmacovigilance, genomics research, blockchain, and medical articles and medico marketing.
TCS provides clinical research services such as clinical data management, regulatory affairs, pharmacovigilance, risk-based monitoring, biostatistics and programming, medical writing, medical affairs and medico marketing, and health economics and outcomes research.
The company’s extensive portfolio of intellectual property – including the award-winning TCS ADD platform suite, Real World Evidence platform, Decision Fabric engine, TCS Connected Clinical Trials platform and Translational Research Platform – helps customers achieve better speed to market and superior business outcomes.
Other solutions include CDISC Review Assistant, Custom Functions Framework and eTMF Indexing Assistant for Clinical Trials, MLR automation and PromoRev for marketing and sales, analytics and compliance support, and Data and Analytics Target Operating Model (DATOM) for operations spanning the complete supply chain.
The TCS ADD platform helps clients transform the entire clinical R&D value chain and makes clinical trials more agile and safe. Powered by a cognitive artificial intelligence engine, data-driven smart analytics and IoT, it drives superior business outcome such as optimized and safer operations.
TCS ended at Rs3,814.75 apiece down by Rs36.3 or 0.94% on Sensex.
#TCS #positioned #Leader #Life #Sciences #Operations #Services #Everest #Group
( With inputs from indiainfoline)